Vivi Ann Flørenes

Publications published between 1992 and 2009 or in press by Vivi Ann Flørenes

70 publications found

Publications in press

1. Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA
   Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
   Cancer Chemother Pharmacol (in press)
   PubMed 22302409

Publications 2009

1. Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, Flørenes VA, Davidson B (2009)
   Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
   Hum Pathol, 40 (6), 795-806
   PubMed 19157506
2. Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
   Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
   Tumour Biol, 30 (1), 15-25
   PubMed 19194111
3. Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B (2009)
   Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
   Hum Pathol, 40 (4), 527-37
   PubMed 19121847

Publications 2008

1. Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Flørenes VA, Kopolovic J, Reich R (2008)
   Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
   Hum Pathol, 39 (1), 87-95
   PubMed 17949781
2. Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B (2008)
   Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
   Cancer, 112 (1), 84-93
   PubMed 17985388
3. Goscinski MA, Suo Z, Flørenes VA, Vlatkovic L, Nesland JM, Giercksky KE (2008)
   FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions
   Ultrastruct Pathol, 32 (3), 89-96
   PubMed 18570153
4. Goscinski MA, Suo ZH, Nesland JM, Chen WT, Zakrzewska M, Wang J, Zhang S, Flørenes VA, Giercksky KE (2008)
   Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China
   Oncology, 75 (1-2), 49-59
   PubMed 18787344
5. Goscinski MA, Suo ZH, Nesland JM, Flørenes VA, Giercksky KE (2008)
   Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines
   APMIS, 116 (9), 823-31
   PubMed 19024603
6. Odlo K, Hentzen J, dit Chabert JF, Ducki S, Gani OA, Sylte I, Skrede M, Flørenes VA, Hansen TV (2008)
   1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
   Bioorg Med Chem, 16 (9), 4829-38
   PubMed 18396050
7. Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA (2008)
   The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
   BMC Cancer, 8, 276
   PubMed 18826602
8. Torlakovic EE, Slipicevic A, Flørenes VA, Chibbar R, DeCoteau JF, Bilalovic N (2008)
   Fli-1 expression in malignant melanoma
   Histol Histopathol, 23 (11), 1309-14
   PubMed 18785112

Publications 2007

1. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
   Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
   Cancer, 110 (6), 1264-71
   PubMed 17647260
2. Kleinberg L, Flørenes VA, Nesland JM, Davidson B (2007)
   Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
   Am J Clin Pathol, 128 (3), 389-97
   PubMed 17709312
3. Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007)
   Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
   Cancer, 109 (2), 228-38
   PubMed 17167759
4. Kleinberg L, Lie AK, Flørenes VA, Nesland JM, Davidson B (2007)
   Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
   Hum Pathol, 38 (7), 986-94
   PubMed 17350081

Publications 2006

1. Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
   Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
   Clin Cancer Res, 12 (3 Pt 1), 791-9
   PubMed 16467090
2. Davidson B, Zhang Z, Kleinberg L, Li M, Flørenes VA, Wang TL, Shih IeM (2006)
   Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
   Clin Cancer Res, 12 (20 Pt 1), 5944-50
   PubMed 17062665
3. Jørgensen K, Davidson B, Flørenes VA (2006)
   Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
   Mod Pathol, 19 (11), 1446-55
   PubMed 16951673
4. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B (2006)
   Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
   Virchows Arch, 449 (1), 31-9
   PubMed 16541284
5. Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA (2006)
   Pax-5 expression in nonhematopoietic tissues
   Am J Clin Pathol, 126 (5), 798-804
   PubMed 17050077
6. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B (2006)
   The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
   Gynecol Oncol, 100 (3), 462-8
   PubMed 16216317

Publications 2005

1. Agesen TH, Flørenes VA, Molenaar WM, Lind GE, Berner JM, Plaat BE, Komdeur R, Myklebost O, van den Berg E, Lothe RA (2005)
   Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors
   J Neuropathol Exp Neurol, 64 (1), 74-81
   PubMed 15715087
2. Jørgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Flørenes VA (2005)
   Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
   Biochem Biophys Res Commun, 329 (1), 266-74
   PubMed 15721302
3. Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
   Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
   Mol Cancer, 4, 26
   PubMed 16042759
4. Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA (2005)
   Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
   Am J Clin Pathol, 124 (4), 528-36
   PubMed 16146807

Publications 2004

1. Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
   Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
   Mod Pathol, 17 (8), 990-7
   PubMed 15133476
2. Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC (2004)
   Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
   Cancer, 100 (10), 2139-47
   PubMed 15139056
3. Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C (2004)
   Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
   Lung Cancer, 44 (2), 159-65
   PubMed 15084380
4. Flørenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B (2004)
   Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
   Am J Clin Pathol, 122 (3), 412-20
   PubMed 15362372
5. Flørenes VA, Skrede M, Jørgensen K, Nesland JM (2004)
   Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
   Melanoma Res, 14 (3), 173-81
   PubMed 15179185
6. Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G, Flørenes VA (2004)
   Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis
   Mod Pathol, 17 (11), 1400-6
   PubMed 15205685

Publications 2003

1. Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
   Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
   Clin Cancer Res, 9 (6), 2248-59
   PubMed 12796393
2. Jørgensen K, Holm R, Maelandsmo GM, Flørenes VA (2003)
   Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome
   Clin Cancer Res, 9 (14), 5325-31
   PubMed 14614017
3. Maelandsmo GM, Holm R, Nesland JM, Fodstad Ø, Flørenes VA (2003)
   Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
   Clin Cancer Res, 9 (9), 3383-8
   PubMed 12960126
4. Skotheim RI, Abeler VM, Nesland JM, Fosså SD, Holm R, Wagner U, Flørenes VA, Aass N, Kallioniemi OP, Lothe RA (2003)
   Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays
   Neoplasia, 5 (5), 397-404
   PubMed 14670177
5. Sudbø J, Reith A, Flørenes VA, Nesland JM, Ristimäki A, Bryne M (2003)
   COX-2 expression in striated muscle under physiological conditions
   Oral Dis, 9 (6), 313-6
   PubMed 14629333

Publications 2002

1. Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
   Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
   Oncogene, 21 (14), 2261-9
   PubMed 11948409
2. Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
   Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
   Anticancer Res, 22 (4), 1949-57
   PubMed 12174869

Publications 2001

1. Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
   Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
   Gynecol Oncol, 83 (2), 249-56
   PubMed 11606079
2. Flørenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001)
   Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome
   J Pathol, 195 (5), 530-6
   PubMed 11745687
3. Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
   Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
   Oncogene, 20 (47), 6881-90
   PubMed 11687967
4. Holm R, Skovlund E, Skomedal H, Flørenes VA, Tanum G (2001)
   Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas
   Histopathology, 39 (1), 43-9
   PubMed 11454043

Publications 2000

1. Flørenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000)
   Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
   Clin Cancer Res, 6 (9), 3614-20
   PubMed 10999753

Publications 1999

1. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC (1999)
   Up-regulation of ephrin-A1 during melanoma progression
   Int J Cancer, 84 (5), 494-501
   PubMed 10502726
2. Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS (1999)
   Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma
   Oncogene, 18 (4), 1023-32
   PubMed 10023678
3. Rak J, Mitsuhashi Y, Sheehan C, Krestow JK, Florenes VA, Filmus J, Kerbel RS (1999)
   Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis
   Neoplasia, 1 (1), 23-30
   PubMed 10935467

Publications 1998

1. Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R (1998)
   Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival
   Am J Pathol, 153 (1), 305-12
   PubMed 9665492
2. St Croix B, Sheehan C, Rak JW, Flørenes VA, Slingerland JM, Kerbel RS (1998)
   E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1)
   J Cell Biol, 142 (2), 557-71
   PubMed 9679152

Publications 1997

1. Easty DJ, Mitchell PJ, Patel K, Flørenes VA, Spritz RA, Bennett DC (1997)
   Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma
   Int J Cancer, 71 (6), 1061-5
   PubMed 9185712
2. Holm R, Flørenes VA, Erikstein B, Nesland JM (1997)
   Expression of stromelysin-3 in medullary carcinoma of the breast
   Anticancer Res, 17 (5B), 3725-7
   PubMed 9427769
3. Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O (1997)
   Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
   Int J Cancer, 74 (4), 464-9
   PubMed 9291441
4. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
   High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
   Clin Cancer Res, 3 (9), 1623-8
   PubMed 9815852

Publications 1996

1. Flørenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, Slingerland JM (1996)
   TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1
   Oncogene, 13 (11), 2447-57
   PubMed 8957087
2. Kerbel RS, St Croix B, Florenes VA, Rak J (1996)
   Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors
   Hum Cell, 9 (4), 257-64
   PubMed 9183656
3. Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
   Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
   Br J Cancer, 73 (8), 909-16
   PubMed 8611425
4. Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Flørenes VA (1996)
   Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions
   Am J Pathol, 149 (6), 1813-22
   PubMed 8952518
5. Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
   Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
   Cancer Res, 56 (23), 5490-8
   PubMed 8968106
6. St Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS (1996)
   Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
   Nat Med, 2 (11), 1204-10
   PubMed 8898746

Publications 1995

1. Flørenes VA, Holm R, Fodstad O (1995)
   Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome
   Melanoma Res, 5 (3), 183-7
   PubMed 7640520
2. Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995)
   Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
   Br J Cancer, 72 (2), 393-8
   PubMed 7640224
3. Wen DY, Hall WA, Conrad J, Godal A, Flørenes VA, Fodstad O (1995)
   In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line
   Neurosurgery, 36 (6), 1158-63; discussion 1163-4
   PubMed 7643997

Publications 1994

1. Flørenes VA, Holm R, Myklebost O, Lendahl U, Fodstad O (1994)
   Expression of the neuroectodermal intermediate filament nestin in human melanomas
   Cancer Res, 54 (2), 354-6
   PubMed 8275467
2. Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994)
   MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status
   J Natl Cancer Inst, 86 (17), 1297-302
   PubMed 8064888
3. Flørenes VA, Oyjord T, Holm R, Skrede M, Børresen AL, Nesland JM, Fodstad O (1994)
   TP53 allele loss, mutations and expression in malignant melanoma
   Br J Cancer, 69 (2), 253-9
   PubMed 7905277
4. Forus A, Flørenes VA, Maelandsmo GM, Fodstad O, Myklebost O (1994)
   The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
   Cancer Genet Cytogenet, 78 (2), 165-71
   PubMed 7828148
5. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ (1994)
   Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme
   Cancer Res, 54 (4), 900-2
   PubMed 8313379

Publications 1993

1. Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
   p53 abnormalities in different subtypes of human sarcomas
   Cancer Res, 53 (3), 468-71
   PubMed 8425179
2. Forus A, Flørenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993)
   Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2
   Cell Growth Differ, 4 (12), 1065-70
   PubMed 8117620

Publications 1992

1. Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
   Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
   Cancer Res, 52 (21), 6088-91
   PubMed 1356624